Hector Alila, D.V.M., Ph.D.
President & C.E.O.
Hector Alila is foundering President and C.E.O. of Esperance Pharmaceuticals. Dr. Alila is a biopharmaceutical industry veteran bringing over 20 years of management, drug development and research experience in large pharmaceutical and biotech industry to Esperance. He served as Senior Vice President of Drug Development at Protalex, Inc. (New Hope, PA), Vice President of Product Development at Cell Pathways, Inc in Horsham, PA, (later acquired by OSI Pharmaceuticals), Director of Biology/Pharmacology at GeneMedicine, Inc. in The Woodlands, TX, (which merged with Megabios to become Valentis, Inc.) and several research, development, and management positions at SmithKline Beecham (now GlaxoSmithKline) in PA. He obtained his Ph.D. degree in physiology and immunology from Cornell University (Ithaca, NY). Dr. Alila has published several scientific papers in peer-reviewed journals and holds several patents.
Carola Leuschner, Dr. rer. Nat., Ph.D.
Senior Director of Biology
For the last decade Dr. Leuschner’s research has focused on the development of anti-cancer drugs and imaging systems for non-invasive cancer detection in applications for prostate, breast, and ovarian cancers as Assistant Professor in the Department of Reproductive Biotechnology at Pennington Biomedical Research Center (PBRC) in Baton Rouge, Louisiana. She also served as an Instructor in the Department of Diet and Heart Disease at the Pennington Biomedical Center. Dr. Leuschner obtained her doctorate degree in Biochemistry at the University of Hannover, Germany with postdoctoral training at the Department of Technical Microbiology of Hamburg University, Germany. She has published two book chapters, over 40 peer reviewed articles and holds several patents. Dr. Leuschner is the recipient of the Nano50 2006 Technology Award.
Vice President, Business Development
Jim has over two decades of leadership experience in the life science industry across a range of strategic and operational roles in business development and commercialization. Before joining Esperance, Jim founded the Freestone Group, a professional and venture services firm supporting emerging life science companies and investors on business and corporate development initiatives. Prior to that, he was at AstraZeneca as Director, Business Development in metabolic disorders as well as Brand Director for Crestor® and Commercial Director for Gastroenterology Emerging Brands. Jim has also held management team and senior leadership positions in corporate and business development, portfolio strategy and commercial operations in both private and public, early stage pharmaceutical companies including VP, Marketing at Biosyn and Director, Marketing at ViroPharma. Earlier in his career, Jim held roles of increasing responsibility at TAP Pharmaceuticals (now Takeda) in marketing of Prevacid® and sales of specialty and primary care products in academic and office settings.